Suchergebnisse - "*Antirheumatic Agents"

1

CADTH reimbursement recommendation : indication: rheumatoid arthritis : recommendation : reimburse with conditionsInfliximab SC (Remsima SC)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, April 2021

CADTH reimbursement review

Version: 1.0.

2

Clinical and economic review report : Celltrion Healthcare Co., Ltd. : indication : rheumatoid arthritisInfliximab SC (Remsima)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, August 2021

CADTH common drug review

Version: Final (with redactions).

3

Triple conventional synthetic disease-modifying anti-rheumatic drugs for the management of rheumatoid arthritis : a review of cost-effectiveness

Erschienen: Ottawa, CADTH, March 26, 2019

CADTH rapid response report

Version: 1.0.

von Williams, D. | Butcher, R.

4

Rheumatology

Erschienen: Philadelphia, PA, Elsevier, [2019]

Seventh edition

von Hochberg, M. | Gravallese, E. | Silman, A. | +4

5

Pharmacoeconomic review report : indication : treatment of adult patients with active psoriatic arthritis who have responded inadequately to, or are intolerant to one or more disease-modifying antirheumatic drugs (DMARD)Ixekizumab (Taltz) (Eli Lilly Canada Inc.)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, August 2018

CADTH common drug review

6

CADTH Canadian Drug Expert Committee recommendation : indication : adult patients with active psoriatic arthritis (PsA) who have responded inadequately to, or are intolerant to one or more disease-modifying antirheumatic drugs (DMARD)Ixekizumab (Taltz -- Eli Lilly Canada Inc.)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, August 2018

CADTH common drug review

Version 1.0.

7

Rituximab maintenance therapy for the treatment and management of rheumatoid arthritis : a review of clinical effectiveness

Erschienen: Ottawa, CADTH, July 04, 2018

CADTH rapid response report: summary with critical appraisal

Version 1.0.

von Singh, K. | McCormack, S.

8

Drugs for the management of rheumatoid arthritis : clinical evaluation

Erschienen: Ottawa, CADTH, March 2018

CADTH health technology assessment - issue 146

von Wells, G.

9

Drug therapy for early rheumatoid arthritis : a systematic review update

Erschienen: Rockville, MD, Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, July 2018

Comparative effectiveness review - number 211

von Donahue, K.

10

CADTH Canadian Drug Expert Committee final recommendation : indication: rheumatoid arthritisSarilumab (Kevzara -- Sanofi Genzyme)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, 2017

CADTH common drug review

Filter & Sortierung